Drug Trial News

RSS

Researchers demonstrate clinical efficacy of gallopamil in severe asthma patients

A team of Inserm researchers from the Cardio-Thoracic Research Centre of Bordeaux (Inserm/University of Bordeaux and Bordeaux University Hospital) has demonstrated the clinical efficacy of gallopamil in 31 patients with severe asthma. This chronic disease is characterised by remodelling of the bronchi, which exacerbates the obstruction of the airways already seen in "classic" asthma.

20 Feb 2015

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Regeneron Pharmaceuticals, Inc. today announced that results from the National Institutes of Health-sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T) were published in the New England Journal of Medicine and a corresponding slide set was posted online at DRCR.net.

20 Feb 2015

New nine-valent HPV vaccine has potential to dramatically reduce cervical cancer rates

A multinational study on a diverse group of women shows that a new nine-valent human papillomavirus (HPV) vaccine prevents infections and disease associated with the vaccine types, according to a paper published today in The New England Journal of Medicine.

19 Feb 2015

Study results pave way for new clinical trial for glioblastoma patients

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research.

19 Feb 2015

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

The HIV Prevention Trials Network has launched two new phase 2 studies, HPTN 076 and HPTN 077, which are designed to evaluate new drugs to protect people from getting infected with HIV.

19 Feb 2015

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).

19 Feb 2015

New clinical trial launched in South Africa to study investigational HIV vaccine regimen

A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants. This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program-led RV144 clinical trial in Thailand--the first study to demonstrate that a vaccine can protect people from HIV infection.

19 Feb 2015

TB Alliance announces initiation of first human trial of new TB drug candidate

TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354. It is the first new TB drug candidate to begin a Phase 1 clinical trial since 2009.

19 Feb 2015

PAREXEL International expands clinical trial site alliance network

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the continued expansion of its clinical trial site alliance network, an extensive network of investigator sites and Site Management Organizations (SMOs) that enables PAREXEL to quickly access and enroll patient populations for clients' clinical trials worldwide.

From Parexel 18 Feb 2015

Oncolytics announces completion of patient enrollment in REOLYSIN Phase II colorectal cancer study

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer (IND 210). The trial is being sponsored and conducted by the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario.

18 Feb 2015

Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1

Among previously untreated adults with Gaucher disease type 1, a genetic disease in which there is improper metabolism due to a defect in an enzyme, treatment with the drug eliglustat resulted in significant improvements in liver and spleen size hemoglobin level, and platelet count, according to a study in the February 17 issue of JAMA.

18 Feb 2015

Anticoagulant fondaparinux lowers risk of major bleeding events, death in heart attack patients

Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in the hospital and after six months compared to patients who received low-molecular-weight heparin (LMWH), although both groups had similar rates of subsequent heart attack or stroke, according to a study in the February 17 issue of JAMA.

18 Feb 2015

World class drug discovery team launches new company to tackle chronic respiratory disease

Respiratory diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD) and severe asthma represent a major unmet medical need and a significant health burden in both the developed and developing world.

16 Feb 2015

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy.

13 Feb 2015

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.

13 Feb 2015

Stem cell transplants more effective than mitoxantrone drug for people with severe multiple sclerosis

Stem cell transplants may be more effective than the drug mitoxantrone for people with severe cases of multiple sclerosis (MS), according to a new study published in the February 11, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Feb 2015

$Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer$

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

12 Feb 2015

USF researchers awarded grant to test new drug for age-related hearing loss

A successful treatment for age-related hearing loss (ARHL) is a step closer to reality, thanks to a group of researchers from the University of South Florida. The research team comprised of faculty and students has been awarded $400,000 by Autifony Therapeutics, Ltd, a company based in the United Kingdom, to test a new drug the company developed for ARHL.

12 Feb 2015

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily.

12 Feb 2015

New breakthrough vaccine could treat Triple Negative breast cancer

26.2 with DONNA The National Marathon to Finish Breast Cancer is thrilled to announce a stunning new development that could mean a vaccine for some women with Triple Negative Breast Cancer, an aggressive type of breast cancer that tends to strike young women, African American women, and women of Hispanic descent.

12 Feb 2015

Drug Trial News

Researchers demonstrate clinical efficacy of gallopamil in severe asthma patients

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

New nine-valent HPV vaccine has potential to dramatically reduce cervical cancer rates

Study results pave way for new clinical trial for glioblastoma patients

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

New clinical trial launched in South Africa to study investigational HIV vaccine regimen

TB Alliance announces initiation of first human trial of new TB drug candidate

PAREXEL International expands clinical trial site alliance network

Oncolytics announces completion of patient enrollment in REOLYSIN Phase II colorectal cancer study

Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1

Anticoagulant fondaparinux lowers risk of major bleeding events, death in heart attack patients

World class drug discovery team launches new company to tackle chronic respiratory disease

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Stem cell transplants more effective than mitoxantrone drug for people with severe multiple sclerosis

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

USF researchers awarded grant to test new drug for age-related hearing loss

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

New breakthrough vaccine could treat Triple Negative breast cancer

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News